SCHEMBL4286299

SCHEMBL4286299

COc1c(C(=O)Cl)ccc(C2CC2)c1C1CC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.33
ALDH1A1 P00352 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SLC6A3 Q01959 2/20 0.33
ABCB1 P08183 1/20 0.33
CNR2 P34972 1/20 0.32
MAPT P10636 1/20 0.32
DRD2 P14416 1/20 0.32
PDK2 Q15119 1/20 0.32
PDK4 Q16654 1/20 0.32
DRD3 P35462 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
GAA P10253 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31
RAB9A P51151 1/20 0.31
TAS1R3 Q7RTX0 1/20 0.31
TAS1R1 Q7RTX1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4388724 0.77 L3MBTL1 (0.34) TDP1ALDH1A1L3MBTL1MAPTPOLB
SCHEMBL27925249 0.76 TDP1 (0.42) TDP1CNR2TAS1R3TAS1R1TAS1R2
SCHEMBL2202238 0.75 TDP1 (0.44) TDP1ALDH1A1MAPTNPC1POLB
SCHEMBL29997568 0.75 TDP1 (0.44) TDP1ALDH1A1MAPTNPC1POLB
SCHEMBL31459988 0.73 PTGDR2 (0.47) ALDH1A1GAANPC1RAB9A
SCHEMBL28277727 0.72 ALDH1A1 (0.47) TDP1ALDH1A1L3MBTL1SLC6A3MAPT
SCHEMBL699716 0.72 ALDH1A1 (0.45) ALDH1A1CNR2GAANPSR1NPC1
SCHEMBL28060622 0.71 TDP1 (0.40) TDP1ALDH1A1CNR2MAPTDRD2
SCHEMBL28110525 0.70 MAPT (0.42) TDP1ALDH1A1L3MBTL1MAPTDRD2
SCHEMBL27868670 0.70 TDP1 (0.46) TDP1ALDH1A1L3MBTL1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202880-B2 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors NYCOMED GMBH (DE) 2012-06-19 US disclosed
US-7632844-B2 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH (DE) 2009-12-15 US disclosed
US-20090170892-A1 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors NYCOMED GMBH (DE) 2009-07-02 US disclosed
US-20080319067-A1 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH 2008-12-25 US disclosed
US-7423046-B2 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors NYCOMED GMBH (DE) 2008-09-09 US disclosed
US-7329676-B2 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH (DE) 2008-02-12 US disclosed
EP-1536798-B1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2007-02-07 EP disclosed
EP-1539164-B1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2006-12-20 EP disclosed
US-20050239818-A1 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors ALANA PHARMA AG (DE) 2005-10-27 US disclosed
US-20050239817-A1 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors ALTANA PHARMA AG (DE) 2005-10-27 US disclosed
EP-1539164-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-15 EP disclosed
EP-1536798-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-08 EP disclosed
WO-2004019944-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed
WO-2004019945-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239817-A1 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors PDE4A, PDE4B, PDE3A TDP1 60/4885ALDH1A1 322/4885L3MBTL1 3938/4885
US-20080319067-A1 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors PDE4A, PDE4B, PDE3A TDP1 60/4885ALDH1A1 322/4885L3MBTL1 3938/4885
US-20050239818-A1 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors PDE4A, PDE4B, PDE3A TDP1 62/4885ALDH1A1 316/4885L3MBTL1 3757/4885
US-20090170892-A1 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors PDE4A, PDE4B, PDE3A TDP1 62/4885ALDH1A1 371/4885L3MBTL1 3763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.